Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method

Por Jerling, Markus, Merlé, Yann, Mentré, France, Mallet, Alain
Publicado em 1997

Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose

Por Hellgren, Urban, Berggren-Palme, Ingela, Bergqvist, Yngve, Jerling, Markus
Publicado em 1997

Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711

Por Lindström, Erik, Rizoska, Biljana, Henderson, Ian, Terelius, Ylva, Jerling, Markus, Edenius, Charlotte, Grabowska, Urszula
Publicado no J Transl Med (2018)

Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen

Por Obua, Celestino, Hellgren, Urban, Ntale, Muhammed, Gustafsson, Lars L, Ogwal-Okeng, Jasper W, Gordi, Toufigh, Jerling, Markus
Publicado em 2008

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

Por Wickström, Malin, Nygren, Peter, Larsson, Rolf, Harmenberg, Johan, Lindberg, Jakob, Sjöberg, Per, Jerling, Markus, Lehmann, Fredrik, Richardson, Paul, Anderson, Kenneth, Chauhan, Dharminder, Gullbo, Joachim
Publicado no Oncotarget (2017)

Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson’s disease patients

Por Paul, Gesine, Zachrisson, Olof, Varrone, Andrea, Almqvist, Per, Jerling, Markus, Lind, Göran, Rehncrona, Stig, Linderoth, Bengt, Bjartmarz, Hjalmar, Shafer, Lisa L., Coffey, Robert, Svensson, Mikael, Mercer, Katarina Jansson, Forsberg, Anton, Halldin, Christer, Svenningsson, Per, Widner, Håkan, Frisén, Jonas, Pålhagen, Sven, Haegerstrand, Anders
Publicado no J Clin Invest (2015)